Deep learning has already had a huge impact on computer vision and speech recognition, and it’s making inroads in areas as computer-unfriendly as cooking. Now a new startup led by University of Toronto professor Brendan Frey wants to cause similar reverberations in genomic medicine.
Deep Genomics plans to identify gene variants and mutations never before observed or studied and find how these link to various diseases. And through this work the company believes it can help usher in a new era of personalized medicine.
Genomic research is hard. Scientists still know relatively little about our genes and how they interrelate. But Frey and others in the field now know enough that they can equip machines to do the heavy lifting. And there’s an awful lot of this heavy lifting to do. “Genomics is no longer about small datasets,” Frey tells Gizmag. “It’s now about very, very large datasets.”
For context, the first effort to sequence a full human genome took 13 years – running from 1990 to 2003. There are now many companies working to sequence many genomes at a time. The largest of these is called Illumina. “Illumina,” Frey says, “expects to sequence one million genomes in the next year. Each genome contains three billion letters. That’s a lot of data.”
To store and make sense of all that data, Deep Genomics built Spidex. The name is a portmanteau of “splicing index,” which basically means that Spidex is a database containing information about how lots and lots of different genetic variants affect (or are likely to affect) RNA splicing – a crucial step in gene expression that edits genes in different ways so that they can produce different kinds of proteins.
If RNA splicing goes off kilter, the consequences could range from nothing in particular to disease and cancer. Spidex is meant to help us separate the harmless variants from the harmful ones, and to understand how they relate to other genetic processes.
Spidex currently includes predictions to the tune of around 328 million such variants and the knock-on effects they pose for RNA splicing. That number is set to grow as the company applies its deep learning algorithms to classifying and interpreting more data.
Frey also notes that the bulk of those variants are in the “junk DNA” part of the genetic code. This is the bit that scientists had previously written off as irrelevant, even though it forms the vast majority of the genome. “Most medical genetic analysis currently deals only with mutations in what are called ‘protein-coding segments’ in DNA, or ‘exons,’ Frey explains. “This makes up only 1.5 percent of the genome.”
Read more: New company plans to revolutionize genomic medicine with deep learning
The Latest on: Genomic medicine
[google_news title=”” keyword=”Genomic medicine” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Genomic medicine
- Fujitsu introduces ‘explainable AI’ for use in genomic medicine and cancer treatment planningon May 9, 2024 at 2:56 pm
Fujitsu on Thursday announced the development of explainable AI technology that automatically draws on data in multiple formats, including text, images, and numerical data, to create knowledge graphs ...
- Advancing The Future Of Medicine By Getting Back To Its Genetic Rootson May 9, 2024 at 12:00 pm
genetic medicines. Unlocking innovation to deliver life-altering therapies to people in need remains our singular vision, with more avenues than ever that will shape the future of medicine.
- Poseida Highlights Strong Progress on Its Genetic Medicine Programs at the American Society for Gene and Cell Therapy 27th Annual Meetingon May 9, 2024 at 7:18 am
NDAQ:PSTX) Poseida Highlights Strong Progress on Its Genetic Medicine Programs at the American Society for Gene and Cell Therapy 27th Annual Meeting ...
- Labroots Announces the 12th Annual Precision Medicine: Genomics, Genetics & Molecular Diagnostics Virtual Event Series 2024on May 9, 2024 at 7:00 am
Labroots, the leading scientific social networking website and producer of educational virtual events and webinars, proudly announces the upcoming 12th Annual Precision Medicine Virtual Event Series.
- Florida Man to Pay $97M for Cancer Genomic Testing, Medicine Compounding Fraudon May 9, 2024 at 6:12 am
The man had, among other things, fraudulently billed Medicare and other healthcare benefit programs for medically unnecessary cancer genomic tests.
- Editas Medicine’s Innovative In Vivo Gene Editing Approach and Positive Clinical Trial Prospects Bolster Buy Ratingon May 9, 2024 at 3:26 am
Editas Medicine (EDIT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst ...
- Elon Musk Breaks Ranks With GOP By Praising Genetic Engineering Tech That Helped Fight COVID-19: 'Digital Medicine With Incredible Potential'on May 9, 2024 at 2:01 am
Tesla CEO Elon Musk does not seem to agree with Republicans at least on one thing. On Wednesday, the billionaire, true to his credentials as a tech pioneer, unequivocally backed the mRNA technology, ...
- Genomics Market to be Worth $70.52 Billion by 2031--Exclusive Report by Meticulous Research®on May 8, 2024 at 7:16 am
Genomics is the study of genes and their function, including genome organization, structure, function, and evolution. It involves analyzing the DNA sequence and studying the interactions between genes ...
- Advancing genomic medicine: National Cancer Center Japan's role in personalized cancer treatmenton May 2, 2024 at 5:00 pm
In a significant stride towards personalized cancer care, the National Cancer Center Japan (NCCJ) has marked a decade of progress in cancer genomic medicine (CGM).
- GSK and Genomics collab to explore using genetics in clinical trial designon April 30, 2024 at 12:20 pm
GSK and Genomics plc will collaborate on a new precision medicine initiative that assesses how genetic data can be used in clinical trial design, Genomics ...
via Bing News